Nitric Oxide

Generic Name: Nitric Oxide

Brand Names: Inomax, Kinox, Noxivent, INOmax

Drug Type: Small Molecule

Chemical Formula: NO

CAS Number: 10102-43-9

Unique Ingredient Identifier: 31C4KY9ESH

Background: Nitric oxide or Nitrogen monoxide is a chemical compound with chemical formula NO. This gas is an important signaling molecule in the body of mammals including humans and is an extremely important intermediate in the chemical industry. It is also a toxic air pollutant produced by automobile engines and power plants.

Nitric oxide (NO) should not be confused with nitrous oxide (N2O), a general anaesthetic, or with nitrogen dioxide (NO2) which is another poisonous air pollutant.

The nitric oxide molecule is a free radical, which is relevant to understanding its high reactivity. It reacts with the ozone in air to form nitrogen dioxide, signalled by the appearance of the reddish-brown color.

Indication: For the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure

Associated Conditions: Hypoxic Respiratory Failure

Associated Therapies: -

Clinical Trials

Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot

Phase 2

Completed

Conditions: Tinea Pedis

Interventions: Drug: Water
Drug: Nitric Oxide

First Posted Date: 2016-08-18

Last Posted Date: 2019-09-20

Lead Sponsor: Nitric Solutions Inc.

Target Recruit Count: 20

Registration Number: NCT02871011

Locations: 🇨🇦
Fairmont Medical Clinic, Vancouver, British Columbia, Canada

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

Phase 3

Active, not recruiting

Conditions: Acute Kidney Injury

Interventions: Other: Placebo
Drug: Nitric Oxide

First Posted Date: 2016-07-19

Last Posted Date: 2022-11-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 250

Registration Number: NCT02836899

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH

Phase 2

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Nitric Oxide

First Posted Date: 2016-04-12

Last Posted Date: 2018-09-24

Lead Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Target Recruit Count: 10

Registration Number: NCT02734953

Locations: 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States

Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin

Phase 4

Terminated

Conditions: Depression
Coronary Artery Disease

Interventions: Drug: Placebo
Drug: No treatment
Drug: Sertraline

First Posted Date: 2015-06-04

Last Posted Date: 2016-05-03

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 2

Registration Number: NCT02463110

Locations: 🇫🇷
ACTION Group - Pitié-Salpêtrière University Hospital (APHP), Paris, France

Role of the Nitric Oxide (NO) in Pre-oxygenation Before Anesthetic Induction in Patients With a Pulmonary Hypertension in Cardiac Surgery. Pilot Study of Feasibility

Phase 2

Conditions: Pulmonary Hypertension

Interventions: Drug: Nitric oxide

First Posted Date: 2015-01-26

Last Posted Date: 2019-02-04

Lead Sponsor: University Hospital, Clermont-Ferrand

Target Recruit Count: 30

Registration Number: NCT02345616

Locations: 🇫🇷
CHU de Clermont-Ferrand, Clermont-Ferrand, France

RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Control
Drug: Nitric Oxide

First Posted Date: 2014-11-20

Last Posted Date: 2024-05-30

Lead Sponsor: University Hospital Southampton NHS Foundation Trust

Target Recruit Count: 12

Registration Number: NCT02295566

Locations: 🇬🇧
University Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom

Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion

Phase 2

Withdrawn

Conditions: Hypertension, Pulmonary
Hemolysis

Interventions: Drug: Nitric Oxide

First Posted Date: 2014-08-15

Last Posted Date: 2016-03-18

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT02217683

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Nitric oxide

First Posted Date: 2013-10-09

Last Posted Date: 2016-06-03

Lead Sponsor: Beyond Air Inc.

Target Recruit Count: 9

Registration Number: NCT01958944

Locations: 🇮🇱
Soroka university, Beer-Sheba, Israel
🇮🇱
Schneider Children's Medical Center of Israel, Petach Tikvah, Israel

Spinal Morphine for Patients With Obstructive Sleep Apnea

Not Applicable

Suspended

Conditions: Obstructive Sleep Apnea

Interventions: Drug: No Intrathecal Morphine
Drug: Intrathecal Morphine

First Posted Date: 2013-02-13

Last Posted Date: 2019-03-19

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 40

Registration Number: NCT01790971

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada

Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With Bronchiolitis

Phase 1

Completed

Conditions: Bronchiolitis

Interventions: Drug: Placebo
Drug: Nitric Oxide

First Posted Date: 2013-01-16

Last Posted Date: 2016-05-04

Lead Sponsor: Beyond Air Inc.

Target Recruit Count: 43

Registration Number: NCT01768884

Locations: 🇮🇱
Soroka university, Beer-Sheba, Israel

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy